The Board of directors of AusCann Group Holdings Limited announced the appointment of global pharmaceutical business executive, Mr. Ido Kanyon, as Chief Executive Officer (CEO), commencing 22nd May 2019. Mr. Kanyon brings more than 15 years' senior executive experience in the pharmaceutical industry most recently at Teva Pharmaceutical Industries. Before taking the leadership of he company, Mr. Kanyon was the Global Head of Specialty Pipeline, Global Marketing and Portfolio at Teva headquarters in the U.S. where he was responsible for the company's Specialty Medicine multi-billion specialty pipeline portfolio with the goal of maximizing the value of the company's R&D investment on innovative medicines. Formerly, he served as a global commercial senior director for Teva's Respiratory business, driving commercial growth for the firm's Respiratory franchise. With the CEO appointment, Interim CEO, Dr. Paul MacLeman, will step back into his role as an Executive Director when Mr. Kanyon commences with the business on 22nd May 2019.